Undurti N. Das
Die Suchergebnisse bei Legimi sind auf die vom Nutzer angegebenen Suchkriterien zugeschnitten. Wir versuchen Titel, die für unsere Nutzer von besonderem Interesse sein könnten, durch die Bezeichnung "Bestseller" oder "Neuheit" hervorzuheben. Titel in der Liste der Suchergebnisse können auch sortiert werden - die Sortierauswahl hat Vorrang vor anderen Ergebnissen."

  • Undurti N. Das 
  • Sprachen: 2 
  • Leeren

Prof. Undurti N. Das is an M.D. in Internal Medicine from Osmania Medical College, Hyderabad, India; Doctor of Science (D.Sc.) from Mangalore University, India, a Fellow of the National Academy of Medical Sciences, India, a fellow of the Royal Society of Chemistry and Shanti Swaroop Bhatnagar prize awardee. Apart from clinical work, he is researching the role of polyunsaturated fatty acids, cytokines, nitric oxide, free radicals, and anti-oxidants in cancer, inflammation, metabolic syndrome, schizophrenia and tropical diseases. His current interests include cancer, molecular biological aspects of diabetes mellitus, hypertension, cardiovascular diseases, autoimmune diseases and metabolic syndrome. Dr. Das was formerly scientist at Efamol Research Institute, Kentville, Canada; Professor of Medicine at Nizam’s Institute of Medical Sciences, Hyderabad, India and Research Professor of Surgery and Nutrition at SUNY Upstate Medical University, Syracuse, USA. At present, he is the Chairman and Research Director of UND Life Sciences LLC, Battle Ground, WA, USA and Chairman and Professor of Medicine at GVP Hospital and Medical College, Visakhapatnam, India and Director of BioScience Research Centre, GVP College of Engineering campus, Visakhapatnam, India serves as a consultant to both Indian and USA based biotech and pharmaceutical companies. Undurti Das is the Editor-in-Chief of the international journal: Lipids in Health and Disease; Academic Editor of Medicine and Review Editor of Nutrition journals and serves on the editorial board of another 10 international journals. Dr. Das has authored more than 500 international publications, wrote 4 books and has been awarded 6 USA patents. He is now developing lipid-based drugs for cancer, diabetes mellitus, lupus and rheumatoid arthritis and sepsis.